C12N 2770/00
Ssrna viruses positive-sense
Official title: ssRNA viruses positive-sense
C12N2770/00 (Ssrna viruses positive-sense) appears on 4,400 US grants and 6,765 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,400
- Published applications
- 6,765
- Assignees
- 2,475
- Inventors
- 12,638
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 9 | 0 |
| 1978 | 10 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 6 | 0 |
| 1982 | 3 | 0 |
| 1983 | 2 | 0 |
| 1984 | 6 | 0 |
| 1985 | 11 | 0 |
| 1986 | 11 | 0 |
| 1987 | 11 | 0 |
| 1988 | 9 | 0 |
| 1989 | 7 | 0 |
| 1990 | 9 | 0 |
| 1991 | 16 | 0 |
| 1992 | 16 | 0 |
| 1993 | 23 | 0 |
| 1994 | 25 | 0 |
| 1995 | 28 | 0 |
| 1996 | 53 | 0 |
| 1997 | 64 | 0 |
| 1998 | 115 | 0 |
| 1999 | 131 | 0 |
| 2000 | 137 | 0 |
| 2001 | 122 | 16 |
| 2002 | 99 | 120 |
| 2003 | 114 | 253 |
| 2004 | 80 | 182 |
| 2005 | 75 | 191 |
| 2006 | 104 | 200 |
| 2007 | 99 | 165 |
| 2008 | 106 | 183 |
| 2009 | 101 | 231 |
| 2010 | 123 | 266 |
| 2011 | 116 | 256 |
| 2012 | 127 | 198 |
| 2013 | 139 | 175 |
| 2014 | 157 | 207 |
| 2015 | 127 | 184 |
| 2016 | 138 | 215 |
| 2017 | 155 | 215 |
| 2018 | 183 | 212 |
| 2019 | 184 | 259 |
| 2020 | 176 | 277 |
| 2021 | 199 | 330 |
| 2022 | 210 | 395 |
| 2023 | 210 | 653 |
| 2024 | 209 | 645 |
| 2025 | 208 | 475 |
| 2026 | 124 | 262 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- High-potency SARS coronavirus 2 antigen and vaccine composition comprising same29 Sep 2026US 12,747,268 B2Korea Research Institute of Chemical Technology
- Variant strain-based coronavirus vaccines22 Sep 2026US 12,741,019 B2ModernaTX, Inc.
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Differential coating of microprojections and microneedles on arrays8 Oct 2026US 2026/0306611 A1Vaxxas Pty Limited
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
Most cited
By later US patents
- Method for processing and preserving collagen-based tissues for transplantation610US 5,336,616 ALifeCell Corporation · 1994
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Synthetic plant genes242US 5,500,365 AMonsanto Company · 1996
- Multiple pharmaceutical dispenser with accumulator207US 5,298,023 AHabley Medical Technology Corporation · 1994